Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05878184 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)
A Phase 1 study of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma, sponsored by Sana Biotechnology.
- Active
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 10
- Study locations
NCT05878184: Active Phase 1 study of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma, sponsored by Sana Biotechnology.
NCT05878184 is a Phase 1 study of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma that is active but no longer recruiting, run by Sana Biotechnology. The registered enrollment target is 16 participants, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (91% lower). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05878184, a Phase 1 study of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma, is active but no longer recruiting, sponsored by Sana Biotechnology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 10
- Study locations
Study Summary
SC291-101 is a Phase 1 study to evaluate SC291 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
Primary Outcome
Safety and Tolerability: Proportion of subjects experiencing adverse events and dose-limiting toxicities
Conditions Studied
Interventions
- DRUG SC291
Study Locations (10)
California
- City of Hope - Duarte
- Stanford Cancer Institute - Palo Alto
Georgia
- Northside Hospital - Atlanta
Kansas
- University of Kansas Medical Center - Fairway
Michigan
- Karmanos Cancer Institute - Detroit
Nebraska
- University of Nebraska Medical Center - Omaha
Texas
- MD Anderson Cancer Center - Houston
South Australia
- Royal Adelaide Hospital - Adelaide
Victoria
- Peter MacCallum Cancer Centre - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-05-02 |
| Est. Completion | 2038-11-04 |
| Phase | Phase 1 |
What the registry record for NCT05878184 still lists
NCT05878184 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which SC291 is the first listed.
NCT05878184 lists 10 locations in 9 states (California, Georgia, Kansas).
Frequently Asked Questions
What is clinical trial NCT05878184 about?
NCT05878184 is a clinical study titled "Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)". SC291-101 is a Phase 1 study to evaluate SC291 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
What is the current status of trial NCT05878184?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2023-05-02. Estimated completion is 2038-11-04.
What conditions does trial NCT05878184 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT05878184?
The interventions under investigation include: SC291 (DRUG).
Who is sponsoring clinical trial NCT05878184?
This trial is sponsored by Sana Biotechnology, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05878184 being conducted?
This trial has 10 study locations across California, Georgia, Kansas, Michigan, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05878184's enrollment target sits among peer trials
16 167th of 187 higher than 16 of 187 other Chronic Lymphocytic Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
RECRUITING · Phase 1
-
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI